Carmelina Capital Partners announces the sale of Florachem

Transaction marks the culmination of Carmelina’s successful partnership with Florachem

LOS ANGELES, May 03, 2022–(BUSINESS WIRE)–A subsidiary of Carmelina Capital, LLC (“Carmelina”), a private investment firm that partners with owner-operators, has completed the sale of Florachem Holdings, LLC (“Florachem” or the “Company”) ) to funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, specialty chemicals and pharmaceuticals industries.

Florachem is a leading manufacturer and supplier of natural herbal ingredients including citrus, pine and specialty rosin resins. The company’s high-quality natural products help its global customer base improve product performance through sustainable and clean ingredients. Florachem partners with industry-leading customers in a variety of end markets including flavors and fragrances, personal care, industrial, coatings and adhesives.

Florachem, led by President and CEO Jon Leonard, is headquartered in Jacksonville, Florida, where it has world-class citrus and pine manufacturing and research and development capabilities. Additionally, the company is completing the construction of a new state-of-the-art food-grade manufacturing facility that will expand Florachem’s capacity, add new capabilities and support the company’s strategic expansion from its product line of natural citrus ingredients.

Massumi + Consoli LLP acted as legal counsel to Carmelina.

About Carmelina Capital Partners

Carmelina Capital Partners is a Los Angeles-based private investment firm that partners with exceptional founder-led, family-owned businesses. Carmelina has extensive experience partnering with owner-operators across a wide range of industries to facilitate shareholder liquidity, support rapid growth and accelerate value creation. For more information, please visit www.carmelina.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220504005101/en/

contacts

Kevin O’Malley
[email protected]

Troy Smildzins
[email protected]

Comments are closed.